Characteristics and temporality of the ventilatory techniques in the management of acute respiratory distress syndrome: A scoping review
, and
Apr 30, 2025
About this article
Article Category: Review
Published Online: Apr 30, 2025
Page range: 122 - 131
Received: Dec 09, 2024
Accepted: Apr 03, 2025
DOI: https://doi.org/10.2478/jccm-2025-0019
Keywords
© 2025 Théo Battalian et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
Fig. 1.

Bibliometric variables
2010–2014 | 4(17,4) |
2015–2019 | 10(43,5) |
2020–2023 | 9(39,1) |
United States | 8(34,8) |
United Kingdom | 6(26,1) |
Switzerland | 2(8,7) |
Others | 7(30,4) |
Review | 1(4,4) |
Observational | 17(73,9) |
Experimental | 5(21,7) |
Conventional oxygen therapy | 3(13,1) |
High Flow Nasal Cannula | 2(8,7) |
Non-invasive ventilation | 7(30,4) |
Invasive ventilation | 17(73,9) |
Combination of strategies | 4(17,3) |
Report of ventilatory record
Coexistence of ventilatory strategies | 5 (22) |
PEEP evaluation | 16 (70) |
Evaluation/record of pulmonary mechanic parameters | 11 (48) |
Report of the time of use of each strategy | 21 (91) |
Report of intervention with Oxygen therapy | 13 (57) |
Report of prone position as a non-ventilatory strategy | 9 (39) |
j_jccm-2025-0019_tab_004
Pubmed 20/10/2023 15h47 UTC+2 | (((“Adult”[Mesh] OR “Adult” OR “Patients”[Mesh] OR “Patients”) AND (“Intensive Care Units”[Mesh] OR “Intensive Care Units”) AND (“Respiratory Distress Syndrome”[Mesh] OR “Respiratory Distress Syndrome” OR “Acute Respiratory Distress Syndrome” OR “ARDS”)) AND ((“Respiratory Therapy”[Mesh] OR “Respiratory Therapy” OR “Respiration, Artificial”[Mesh] OR “Respiration, Artificial”) OR (“Therapeutics”[Mesh] OR “Therapeutics”) OR “Treatment” OR (“Noninvasive Ventilation”[Majr] OR “Noninvasive Ventilation” OR “Intubation, Intratracheal”[Majr] OR “Intubation, Intratracheal” OR “Intubation”[Mesh] OR “Endotracheal Intubation” OR “High Flow Nasal Canula” OR “HFNC” OR “High Flow Oxygen Therapy” OR “HFOT”)) AND (“Time”[Mesh] OR “Time” OR “Timing” OR “Time-to-Treatment”[Mesh] OR “Time-to-Treatment” OR “Time Management”[Mesh] OR “Time Management”)) [FILTERS: 10 YEARS - HUMAN - ADULTS +19] | 297 |
Science direct 25/10/2023 18h49 UTC+2 | “intensive care unit” AND (“Acute Respiratory Distress Syndrome” OR “ARDS”) AND (“Ventilation” OR Noninvasive Ventilation OR Intubation OR “High Flow Nasal Cannula” OR High Flow Oxygen Therapy) AND time | 61 |
EBSCO 26/10/2023 16h51 UTC+2 | (((“Adult”[Mesh] OR “Adult” OR “Patients”[Mesh] OR “Patients”) AND (“Intensive Care Units”[Mesh] OR “Intensive Care Units”) AND (“Respiratory Distress Syndrome”[Mesh] OR “Respiratory Distress Syndrome” OR “Acute Respiratory Distress Syndrome” OR “ARDS”)) AND ((“Respiratory Therapy”[Mesh] OR “Respiratory Therapy” OR “Respiration, Artificial”[Mesh] OR “Respiration, Artificial”) OR (“Therapeutics”[Mesh] OR “Therapeutics”) OR “Treatment” OR (“Noninvasive Ventilation”[Majr] OR “Noninvasive Ventilation” OR “Intubation, Intratracheal”[Majr] OR “Intubation, Intratracheal” OR “Intubation”[Mesh] OR “Endotracheal Intubation” OR “High Flow Nasal Canula” OR “HFNC” OR “High Flow Oxygen Therapy” | 79 |
Academic search CINHAL Sportsdiscuss EJournals |
Reported outcomes from the selected articles
Reported ARDS severity level (PaO2/FiO2) | (30,4) |
14(61) | |
ICU length of stay | 11(48) |
ICU mortality | 10(43) |
Duration of ventilation | 8(35) |
Hospital length of stay | 8(35) |
Follow-up mortality rate | 6(26) |
Complications | 3(13) |
Non-invasive ventilation failure | 6(26) |
Hospital mortality | 14(61) |
Other | |
Temporality | 8(35) |
Quality of life | 0(0) |
PaO2/FiO2 | 19(83) |
pH | 4(17) |
SaO2 | 3(13) |
PaO2 | 2(9) |
PaCO2 | 3(13) |
Bicarbonate | 2(9) |
Lactate | 2(9) |
Oxygen index | 2(9) |
Other | 5(22) |